Zepbound Approved for Sleep apnea
This is a news story, published by Gizmodo, that relates primarily to Zepbound news.
Zepbound news
For more Zepbound news, you can click here:
more Zepbound newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsGizmodo news
For more news from Gizmodo, you can click here:
more news from GizmodoAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
sleep apnea treatment. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest obstructive sleep apnea news, severe obstructive sleep apnea news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
sleep apneaGizmodo
•Health
Health
Popular Weight Loss Drug Zepbound Gains FDA Approval to Treat Sleep Apnea

79% Informative
Zepbound is now the first prescription drug approved for obstructive sleep apnea.
The FDA expanded the approval of Eli Lilly’s obesity drug to explicitly cover sleep apnenea as well.
The drug helped people lose weight and reduce their apnea symptoms in two large-scale clinical trials.
VR Score
79
Informative language
79
Neutral language
38
Article tone
formal
Language
English
Language complexity
54
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
2
Source diversity
2
Affiliate links
no affiliate links